FDA Panel OKs Cholesterol-Lowering Drug
But long-term results still need to be studied.
Get the Beast Digest newsletter delivered straight to your inbox
By clicking “SIGN UP” you agree to our Terms of Use and Privacy Policy.
A Food and Drug Administration advisory panel gave the go-ahead Wednesday to a new cholesterol-lowering drug from Amgen Inc. for patients with dangerously high cholesterol. The drug, Repatha, appears to be effective at lowering cholesterol, but long-term results are still needed to evaluate its overall benefit. An Amgen-sponsored study on the drug’s long-term results will not be complete until 2017. The FDA often follows the panel’s advice but is not required to do so.
Unlock a year of full access to The Daily Beast for $35.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Looks like you already have a subscription!
- Account (completed)
- Payment (completed)
- Confirmation (completed)
You're all set!
Thanks for subscribing.
- 1Account
- 2Payment
- 3Confirmation
Sign in or create an account
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
- Account (completed)
- Payment (completed)
- Confirmation (completed)
You're all set!
Thanks for subscribing.
- 1Account
- 2Payment
- 3Confirmation